The Latest Breaking News from LLY

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

Eli Lilly stock pulled back from bullish gains Tuesday despite strong weight-loss drug sales and a promising test in liver disease treatment.

The S&P 500 rebounded last week near record highs, but is up just 0.2% so far in 2024. These are the index's top performers so far.

Eli Lilly (LLY) is showing elevated implied volatility with an IV Percentile of 98%, and that could mean it’s a good time for an iron condor trade.

The pharmaceutical industry’s future is increasingly promising, spurred by a rise in healthcare expenditure amid escalating chronic and rare disease cases and a burgeoning aged population. The industry's bright outlook is also strengthened by consistent forays into research and development. Against this backdrop, quality pharma stocks Pacira BioSciences (PCRX), Eli…

Alphabet unit Isomorphic Labs, which uses AI to help discover new drugs, entered collaboration deals with Eli Lilly and Novartis.

Dow Jones futures fell as the FAA grounded many Boeing 737 Max-9 jets after a midair incident on Friday. Can the market rally hold key levels?

The major indexes held up Thursday with bullish action from many leading stocks. The December jobs report and spot Bitcoin ETF approvals loom.

Eli Lilly is looking to deliver its anti-obesity treatments directly to consumers while warning against their use for 'cosmetic' weight loss.